Get the Stockscreener App
199.23
0.10%
0.20
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Ligand Pharmaceuticals Inc stock is traded at $199.23, with a volume of 264.57K.
It is up +0.10% in the last 24 hours and up +6.73% over the past month.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
See More
Previous Close:
$199.03
Open:
$199.49
24h Volume:
264.57K
Relative Volume:
1.36
Market Cap:
$3.92B
Revenue:
$152.42M
Net Income/Loss:
$45.24M
P/E Ratio:
79.37
EPS:
2.51
Net Cash Flow:
$6.97M
1W Performance:
-0.81%
1M Performance:
+6.73%
6M Performance:
+94.47%
1Y Performance:
+70.94%
1-Day Range:
$198.90
$204.27
1-Week Range:
$198.82
$210.76
52-Week Range:
$93.58
$212.49
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Name
Ligand Pharmaceuticals Inc
Sector
Industry
Phone
858-550-7500
Address
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
199.23 | 3.92B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Stifel | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Resumed | Stephens | Overweight |
| Feb-04-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-06-20 | Initiated | Barclays | Overweight |
| Mar-24-20 | Downgrade | Argus | Buy → Hold |
| Mar-10-20 | Initiated | Guggenheim | Neutral |
| Feb-06-20 | Initiated | The Benchmark Company | Buy |
| Sep-19-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-03-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-06-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Oct-02-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-18 | Reiterated | Argus | Buy |
| Aug-17-18 | Initiated | Goldman | Neutral |
| Aug-08-18 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-21-18 | Initiated | Argus | Buy |
| Dec-27-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-17 | Resumed | H.C. Wainwright | Buy |
| Oct-05-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-16 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-11-16 | Initiated | Sidoti | Buy |
| Mar-03-16 | Initiated | H.C. Wainwright | Buy |
View All
Ligand Pharmaceuticals Inc Stock (LGND) Latest News
Is Ligand Pharmaceuticals Incorporated (LGDN) stock testing key supportPortfolio Return Report & Stepwise Swing Trade Plans - newser.com
Will Ligand Pharmaceuticals Incorporated (LGDN) stock hit analyst forecastsQuarterly Trade Review & Entry and Exit Point Strategies - newser.com
Will Ligand Pharmaceuticals Incorporated stock attract ESG investorsJuly 2025 Closing Moves & Low Risk Investment Opportunities - newser.com
Is Ligand Pharmaceuticals Incorporated stock positioned for long term growth2025 Market Trends & Detailed Earnings Play Strategies - newser.com
Why Ligand Pharmaceuticals Incorporated (LGDN) stock is favored by hedge fundsPortfolio Gains Report & Real-Time Sentiment Analysis - newser.com
Ligand Pharmaceuticals (LGND): Assessing Valuation After Strong Recent Share Price Gains - Yahoo Finance
This Fund Sold $9 Million of Ligand Stock After an 84% Rally — What Investors Should Know - AOL.com
Is Ligand Pharmaceuticals Incorporated (LGDN) stock good for long term investingCPI Data & Weekly Setup with High ROI Potential - newser.com
Will Ligand Pharmaceuticals Incorporated (LGDN) stock outperform foreign stocks2025 Fundamental Recap & Daily Technical Forecast Reports - newser.com
How Ligand Pharmaceuticals’ Strong Q3 Results and Raised Guidance May Impact LGND Investors - Yahoo Finance
How strong is Ligand Pharmaceuticals Incorporated (LGDN) stock earnings growthMarket Performance Report & Verified Short-Term Trading Plans - newser.com
Intraday pattern recognizer results for Ligand Pharmaceuticals Incorporated - newser.com
What Makes Ligand Pharmaceuticals (LGND) an Investment Choice? - Yahoo Finance
How supply chain issues affect Ligand Pharmaceuticals Incorporated stockWeekly Gains Summary & Daily Stock Trend Watchlist - newser.com
How Ligand Pharmaceuticals Incorporated (LGDN) stock performs during market turbulenceJuly 2025 Opening Moves & Expert Verified Stock Movement Alerts - newser.com
Is Ligand Pharmaceuticals Incorporated reversing from oversold territoryPortfolio Performance Summary & Fast Entry High Yield Tips - newser.com
Virtual Meeting Set for Ligand Pharmaceuticals (LGND) on November 25 - GuruFocus
Ligand Pharmaceuticals (LGND) Price Target Increased by 24.57% to 232.69 - Nasdaq
What moving averages say about Ligand Pharmaceuticals Incorporated2025 Momentum Check & Verified High Yield Trade Plans - newser.com
Ligand Pharmaceuticals Inc Stock (LGND) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):